Circulate
Circulate Health delivers Therapeutic Plasma Exchange (TPE) treatments through a partner-clinic network, targeting longevity seekers, autoimmune patients, and high-performance individuals seeking biological age reduction and microplastics removal on a self-pay basis.
- Company typePrivate
- Founded2022
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Circulate does
Circulate Health, Inc. is a private biotechnology company that delivers Therapeutic Plasma Exchange (TPE) treatments through a network of partner clinics in the United States and the United Kingdom. Founded in 2023 and headquartered in Novato, California, the company has built its clinical protocols on foundational research from the Buck Institute for Research on Aging and holds what it describes as proprietary IP over TPE protocols designed specifically for longevity applications. Its clinical evidence base includes an Aging Cell publication showing an average 2.6-year reduction in biological age after six TPE sessions and what the company characterizes as the first human clinical trial demonstrating measurable reduction of circulating microplastics via TPE.
The company's core product is an FDA-cleared apheresis procedure in which patient blood plasma is separated and replaced with a substitute fluid (typically albumin mixed with saline) to reduce inflammatory factors, aging biomarkers, and microplastics. Supporting offerings include blood-based microplastics diagnostic testing for baseline measurement and longitudinal tracking. Circulate operates a B2B2C turnkey delivery model: it supplies specialized apheresis nurses, FDA-cleared equipment, standardized protocols, quality assurance, supply management, and customer success support to partner clinics, which maintain the patient relationship and billing. Patients are acquired primarily through the company's direct-to-consumer digital marketing and self-refer via the website, with pricing structured as self-pay per session or per protocol (superbills available for potential insurance reimbursement). Active partner clinics span California, Florida, New York, Texas, Utah, Washington, and Colorado, with additional US markets and the Bahamas listed as coming soon and an exclusive UK partnership with Reborne hospital marking its first international expansion in 2026.
Circulate firmographics
Firmographics- Name
- Circulate
- Legal name
- Circulate Health, Inc.
- Website
- https://www.circulate.health
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Circulate Health delivers Therapeutic Plasma Exchange (TPE) treatments through a partner-clinic network, targeting longevity seekers, autoimmune patients, and high-performance individuals seeking biological age reduction and microplastics removal on a self-pay basis.
- Ownership category
- akta.pro rank
Circulate industry classification
Industry- Product category
- Therapeutic Apheresis Services
- NAICS
- Blood and Organ Banks (621991), Services for the Elderly and Persons with Disabilities (62412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)
- akta.pro secondary industries
- Healthy Aging & Cognitive Support Supplements (CRADAGAM), Plasma-Derived & Blood Products Distributors (HLAIAJAJ)
Keywords
Where Circulate is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices15 records
Markets served
Circulate business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Therapeutic Plasma Exchange (TPE) Treatments: Revenue is generated on a per-session or per-treatment-protocol basis. Patients typically self-pay for TPE procedures delivered through Circulate's partner clinic network. Treatment pricing varies based on the number of sessions, individual goals, and the clinical approach recommended by the provider. Circulate provides the nursing staff, equipment, protocols, and operational support to partner clinics, which bill or collect from patients.
- Partner Clinic Services: Circulate provides a turnkey clinical service to partner clinics — staffing expert apheresis nurses, providing FDA-cleared equipment, standardized protocols, quality assurance, supply management, marketing support, and customer success support. Revenue is derived from the services rendered to clinics as part of the treatment delivery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Self-pay TPE treatment — pricing varies by individual protocol and number of sessions |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Circulate product offering
Product offeringCore offering
Circulate provides Therapeutic Plasma Exchange (TPE), an FDA-cleared apheresis procedure that separates and replaces blood plasma to reduce inflammatory factors, age-related biomarkers, and circulating microplastics. The company delivers TPE through a B2B2C model: it equips partner clinics with expert apheresis nurses, FDA-cleared equipment, proprietary standardized protocols, and operational support, while patients are acquired through direct-to-consumer marketing. Supporting offerings include microplastics blood testing and clinical research on aging biomarkers.
Product overview
Circulate offers Therapeutic Plasma Exchange (TPE) as its core clinical offering, an FDA-cleared apheresis procedure delivered through a growing network of partner longevity clinics. The company operates on a platform-plus-partner model: Circulate provides the specialized apheresis nurses, FDA-cleared equipment, standardized clinical protocols, and outcomes tracking, while partner clinics maintain ownership of the patient relationship. Supporting offerings include microplastics blood testing to measure and track plastic particle burden, and clinical research programs that generate evidence for TPE's effects on aging biomarkers.
Differentiator
Problem solved
Functional benefit
Products and services
- Therapeutic Plasma Exchange (TPE) FDA-cleared apheresis procedure in which blood plasma is separated and replaced with substitute fluid (typically albumin mixed with saline) to reduce inflammatory factors, age-related biomarkers, and circulating microplastics. Delivered to patients through Circulate's network of partner longevity and medical clinics using company-supplied apheresis nurses, equipment, and proprietary protocols.
- Microplastics Blood Testing Blood-based diagnostic test that quantifies the number of microplastic particles circulating in a patient's bloodstream, providing a baseline measure of exposure and allowing tracking of changes over time, including reductions associated with TPE treatment.
- Partner Clinic TPE Program (Turnkey Clinical Service for Clinics) Turnkey clinical service package for partner clinics that includes expert apheresis nurses, FDA-cleared equipment, proprietary standardized protocols, quality assurance, supply management, and marketing and customer success support, enabling independent clinics to offer TPE without standing up the operational capability themselves.
Quantifiable outcome
- Average 2.6-year reduction in biological age after six TPE sessions (clinical trial published in Aging Cell)
- +4 more outcomes
Companies that use Circulate
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Circulate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Circulate partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- RebornecoreExclusive partnership making Reborne the first UK hospital to offer Circulate Health's therapeutic plasma exchange (TPE) procedures. This is Circulate's first partnership in Europe, marking the company's international expansion beyond its US-based network of longevity clinics. Reborne will deliver TPE treatments using Circulate's standardized protocols.
- GlycanAgecoreCirculate co-authored landmark research with GlycanAge validating IgG glycans as a predictive biomarker of all-cause mortality and biological aging. The study found that TPE produced the greatest per-month reduction in glycan age among three geroprotective interventions tested. GlycanAge raised an $8.7 million funding round in December 2025 to accelerate clinical adoption of glycan-based diagnostics alongside Circulate.
- Buck Institute for Research on AgingcoreCirculate was founded on research from the Buck Institute for Research on Aging. The company co-authored the landmark glycan aging biomarker study with Buck Institute investigators alongside more than 20 other institutions. The Buck Institute research foundation underpins Circulate's evidence-based TPE protocols for longevity.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Circulate competitors and assessment
Company assessmentDirect peers
- Elysium Health: Elysium develops evidence-based longevity products including the Index supplement and biological age test, targeting affluent consumers interested in measurable healthspan. It overlaps with Circulate's consumer longevity audience and biological age value proposition.
- GlycanAge: GlycanAge offers glycan-based biological age testing and is Circulate's co-research partner on the landmark IgG glycan biomarker study. As both a strategic partner and a competing/complementary diagnostic in the longevity space, it is a closely aligned peer.
- Fountain Life: Fountain Life operates a network of longevity and preventive health centers offering advanced diagnostics and interventions to affluent consumers. It is a direct competitor to Circulate in the premium longevity clinic space, with overlapping B2B2C and DTC dynamics and a focus on measurable healthspan outcomes.
- TruDiagnostic: TruDiagnostic provides epigenetic and biological age testing (including DunedinPACE and GrimAge) for consumers and clinicians. It competes in the same biological age measurement and longevity intervention-tracking space as Circulate's biomarker outcomes platform.
- Human Longevity Inc. HLI provides comprehensive longevity medicine combining whole-genome sequencing, advanced imaging, and personalized health programs. It targets the same high-end consumer seeking biological age reduction and proactive health optimization, making it a direct peer in the longevity medicine category.
- NOVOS: NOVOS offers longevity supplements and biological age testing aimed at consumers seeking to slow aging. It targets a similar self-pay longevity consumer and competes for share of wallet on evidence-based longevity interventions.
Broad incumbents
- Alkahest: Alkahest (a Grifols subsidiary) develops plasma-based therapeutics targeting age-related diseases. While focused on pharmaceutical plasma fractionation rather than TPE procedures, it is the closest plasma-and-aging biotech peer and signals broader industry interest in plasma-based longevity science.
Emerging players
- BioAge Labs: BioAge Labs is a clinical-stage biotechnology company developing drugs that target the biology of aging. While focused on small-molecule therapeutics rather than procedures, it competes in the broader longevity science arena and shares the goal of evidence-backed healthspan extension.
- Elevian: Elevian is a longevity biotech developing recombinant GDF11-based therapies to promote healthy aging. As an emerging research-stage player targeting aging biology through blood/plasma-related mechanisms, it represents an alternative scientific approach to the same longevity opportunity Circulate addresses.
- InsideTracker: InsideTracker offers blood biomarker-based personalized health and longevity insights for consumers. While not a TPE provider, it competes for the same healthspan-focused consumer attention and shares DTC marketing dynamics with Circulate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Circulate social profiles
Digital presenceCirculate financial estimates
Financial estimateRevenue estimate
Valuation estimate
Circulate leadership team
Management profileNumber of profiles
Profiles2 records
Circulate funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Circulate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Circulate
What does Circulate do?
Circulate provides Therapeutic Plasma Exchange (TPE), an FDA-cleared apheresis procedure that separates and replaces blood plasma to reduce inflammatory factors, age-related biomarkers, and circulating microplastics. The company delivers TPE through a B2B2C model: it equips partner clinics with expert apheresis nurses, FDA-cleared equipment, proprietary standardized protocols, and operational support, while patients are acquired through direct-to-consumer marketing. Supporting offerings include microplastics blood testing and clinical research on aging biomarkers.
Is Circulate a public or private company?
Circulate is a private company. It is classified as venture growth investor backed and is currently operating.
When was Circulate founded?
Circulate was founded in 2022. It employs 11 to 50 people.
Where is Circulate based?
Circulate is headquartered in Seattle, United States, in the North America region.
How does Circulate make money?
Two revenue lines are on record. Therapeutic Plasma Exchange (TPE) Treatments are the primary driver. The others are partner Clinic Services.
Who are Circulate's main competitors?
Direct peers on record are Elysium Health, GlycanAge, Fountain Life, TruDiagnostic, Human Longevity Inc. and NOVOS. Alkahest is listed as a broad incumbent. Emerging players are BioAge Labs, Elevian and InsideTracker.
Does Circulate have an API?
No public API is recorded for Circulate.
What industry is Circulate in?
Circulate's product category is Therapeutic Apheresis Services. Its primary akta.pro industry code is HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors), with a secondary code of CRADAGAM, Healthy Aging & Cognitive Support Supplements. Its NAICS code is 621991 and its SIC code is 2836.